Global Malignant Ascites Treatment Market Size, Share, Trends and Forecast 2022-2030

Description

The most common malignancies associated with the development of ascites include cancers of the colon/rectum, ovary, breast, lung, pancreas, liver and lymphoma. Treatment strategies include paracentesis, diuretics and peritoneovenous shunts and so on.
Industry Insights

The global Malignant Ascites Treatment market size is projected to reach US$ 674.6 million by 2028, from US$ 484 million in 2021, at a CAGR of 4.8% during 2022-2028.

Global Malignant Ascites Treatment key players include BD, B. Braun, Pfizer, Merit Medical Systems, Pfm Medical Ag, etc. Global top five manufacturers hold a share about 40%. North America is the largest market, with a share about 30%, followed by Europe and Middle East & Africa, both have a share about 60 percent. In terms of product, Paracentesis is the largest segment, with a share over 65%.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Malignant Ascites Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Malignant Ascites Treatment market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Malignant Ascites Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Malignant Ascites Treatment market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Malignant Ascites Treatment market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Malignant Ascites Treatment Breakdown Data by Type

Paracentesis

Chemotherapy

Surgical Treatment

Others

Malignant Ascites Treatment Breakdown Data by Application

Hospitals

Clinics

Homecare

Others

Regional Analysis

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

BD

Pfizer

B. Braun

Merit Medical Systems

Pfm Medical Ag

Medtronic

CMP Pharma

GI Supply (Laborie Medical Technologies)

The Surgical Company Group

Sequana Medical

PharmaCyte Biotech

BioVie

Clover Biopharmaceuticals

TABLE OF CONTENT

1 Report Overview
1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Malignant Ascites Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 Paracentesis

1.2.3 Chemotherapy

1.2.4 Surgical Treatment

1.2.5 Others

1.3 Market by Application

1.3.1 Global Malignant Ascites Treatment Market Share by Application: 2017 VS 2021 VS 2028

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Homecare

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Malignant Ascites Treatment Market Perspective (2017-2028)

2.2 Malignant Ascites Treatment Growth Trends by Region

2.2.1 Malignant Ascites Treatment Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Malignant Ascites Treatment Historic Market Size by Region (2017-2022)

2.2.3 Malignant Ascites Treatment Forecasted Market Size by Region (2023-2028)

2.3 Malignant Ascites Treatment Market Dynamics

2.3.1 Malignant Ascites Treatment Industry Trends

2.3.2 Malignant Ascites Treatment Market Drivers

2.3.3 Malignant Ascites Treatment Market Challenges

2.3.4 Malignant Ascites Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Malignant Ascites Treatment Players by Revenue

3.1.1 Global Top Malignant Ascites Treatment Players by Revenue (2017-2022)

3.1.2 Global Malignant Ascites Treatment Revenue Market Share by Players (2017-2022)

3.2 Global Malignant Ascites Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Malignant Ascites Treatment Revenue

3.4 Global Malignant Ascites Treatment Market Concentration Ratio

3.4.1 Global Malignant Ascites Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Malignant Ascites Treatment Revenue in 2021

3.5 Malignant Ascites Treatment Key Players Head office and Area Served

3.6 Key Players Malignant Ascites Treatment Product Solution and Service

3.7 Date of Enter into Malignant Ascites Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Malignant Ascites Treatment Breakdown Data by Type

4.1 Global Malignant Ascites Treatment Historic Market Size by Type (2017-2022)

4.2 Global Malignant Ascites Treatment Forecasted Market Size by Type (2023-2028)

5 Malignant Ascites Treatment Breakdown Data by Application

5.1 Global Malignant Ascites Treatment Historic Market Size by Application (2017-2022)

5.2 Global Malignant Ascites Treatment Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America Malignant Ascites Treatment Market Size (2017-2028)

6.2 North America Malignant Ascites Treatment Market Size by Country (2017-2022)

6.3 North America Malignant Ascites Treatment Market Size by Country (2023-2028)

6.4 United States

6.5 Canada

7 Europe

7.1 Europe Malignant Ascites Treatment Market Size (2017-2028)

7.2 Europe Malignant Ascites Treatment Market Size by Country (2017-2022)

7.3 Europe Malignant Ascites Treatment Market Size by Country (2023-2028)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Malignant Ascites Treatment Market Size (2017-2028)

8.2 Asia-Pacific Malignant Ascites Treatment Market Size by Country (2017-2022)

8.3 Asia-Pacific Malignant Ascites Treatment Market Size by Country (2023-2028)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

9 Latin America

9.1 Latin America Malignant Ascites Treatment Market Size (2017-2028)

9.2 Latin America Malignant Ascites Treatment Market Size by Country (2017-2022)

9.3 Latin America Malignant Ascites Treatment Market Size by Country (2023-2028)

9.4 Mexico

9.5 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Malignant Ascites Treatment Market Size (2017-2028)

10.2 Middle East & Africa Malignant Ascites Treatment Market Size by Country (2017-2022)

10.3 Middle East & Africa Malignant Ascites Treatment Market Size by Country (2023-2028)

10.4 Turkey

10.5 Saudi Arabia

10.6 UAE

11 Key Players Profiles

11.1 BD

11.1.1 BD Company Detail

11.1.2 BD Business Overview

11.1.3 BD Malignant Ascites Treatment Introduction

11.1.4 BD Revenue in Malignant Ascites Treatment Business (2017-2022)

11.1.5 BD Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Detail

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Malignant Ascites Treatment Introduction

11.2.4 Pfizer Revenue in Malignant Ascites Treatment Business (2017-2022)

11.2.5 Pfizer Recent Development

11.3 B. Braun

11.3.1 B. Braun Company Detail

11.3.2 B. Braun Business Overview

11.3.3 B. Braun Malignant Ascites Treatment Introduction

11.3.4 B. Braun Revenue in Malignant Ascites Treatment Business (2017-2022)

11.3.5 B. Braun Recent Development

11.4 Merit Medical Systems

11.4.1 Merit Medical Systems Company Detail

11.4.2 Merit Medical Systems Business Overview

11.4.3 Merit Medical Systems Malignant Ascites Treatment Introduction

11.4.4 Merit Medical Systems Revenue in Malignant Ascites Treatment Business (2017-2022)

11.4.5 Merit Medical Systems Recent Development

11.5 Pfm Medical Ag

11.5.1 Pfm Medical Ag Company Detail

11.5.2 Pfm Medical Ag Business Overview

11.5.3 Pfm Medical Ag Malignant Ascites Treatment Introduction

11.5.4 Pfm Medical Ag Revenue in Malignant Ascites Treatment Business (2017-2022)

11.5.5 Pfm Medical Ag Recent Development

11.6 Medtronic

11.6.1 Medtronic Company Detail

11.6.2 Medtronic Business Overview

11.6.3 Medtronic Malignant Ascites Treatment Introduction

11.6.4 Medtronic Revenue in Malignant Ascites Treatment Business (2017-2022)

11.6.5 Medtronic Recent Development

11.7 CMP Pharma

11.7.1 CMP Pharma Company Detail

11.7.2 CMP Pharma Business Overview

11.7.3 CMP Pharma Malignant Ascites Treatment Introduction

11.7.4 CMP Pharma Revenue in Malignant Ascites Treatment Business (2017-2022)

11.7.5 CMP Pharma Recent Development

11.8 GI Supply (Laborie Medical Technologies)

11.8.1 GI Supply (Laborie Medical Technologies) Company Detail

11.8.2 GI Supply (Laborie Medical Technologies) Business Overview

11.8.3 GI Supply (Laborie Medical Technologies) Malignant Ascites Treatment Introduction

11.8.4 GI Supply (Laborie Medical Technologies) Revenue in Malignant Ascites Treatment Business (2017-2022)

11.8.5 GI Supply (Laborie Medical Technologies) Recent Development

11.9 The Surgical Company Group

11.9.1 The Surgical Company Group Company Detail

11.9.2 The Surgical Company Group Business Overview

11.9.3 The Surgical Company Group Malignant Ascites Treatment Introduction

11.9.4 The Surgical Company Group Revenue in Malignant Ascites Treatment Business (2017-2022)

11.9.5 The Surgical Company Group Recent Development

11.10 Sequana Medical

11.10.1 Sequana Medical Company Detail

11.10.2 Sequana Medical Business Overview

11.10.3 Sequana Medical Malignant Ascites Treatment Introduction

11.10.4 Sequana Medical Revenue in Malignant Ascites Treatment Business (2017-2022)

11.10.5 Sequana Medical Recent Development

11.11 PharmaCyte Biotech

11.11.1 PharmaCyte Biotech Company Detail

11.11.2 PharmaCyte Biotech Business Overview

11.11.3 PharmaCyte Biotech Malignant Ascites Treatment Introduction

11.11.4 PharmaCyte Biotech Revenue in Malignant Ascites Treatment Business (2017-2022)

11.11.5 PharmaCyte Biotech Recent Development

11.12 BioVie

11.12.1 BioVie Company Detail

11.12.2 BioVie Business Overview

11.12.3 BioVie Malignant Ascites Treatment Introduction

11.12.4 BioVie Revenue in Malignant Ascites Treatment Business (2017-2022)

11.12.5 BioVie Recent Development

11.13 Clover Biopharmaceuticals

11.13.1 Clover Biopharmaceuticals Company Detail

11.13.2 Clover Biopharmaceuticals Business Overview

11.13.3 Clover Biopharmaceuticals Malignant Ascites Treatment Introduction

11.13.4 Clover Biopharmaceuticals Revenue in Malignant Ascites Treatment Business (2017-2022)

11.13.5 Clover Biopharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

Choose License Type

Checkout Inquiry Sample